CC-93269

DRUG2 trials

Sponsors

Hayakawa Jin, Celgene

Conditions

Multiple MyelomaRelapsed and refractory multiple myeloma

Phase 1

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma

TerminatedNCT03486067

CelgeneMultiple Myeloma

Start: 2018-04-03End: 2025-03-18Updated: 2025-04-17

A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects with Relapsed and Refractory Multiple Myeloma

Active, not recruitingJPRN-jRCT2051230108

Hayakawa JinRelapsed and refractory multiple myeloma

Start: 2023-10-16Target: 12Updated: 2026-06-29

Related Papers

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Blood2023-11-0231 citations

P883: ALNUCTAMAB (ALNUC; BMS-986349; CC-93269), A BCMA × CD3 T-CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST-IN-HUMAN CLINICAL STUDY

HemaSphere2023-08-0114 citations

P799: SYNERGISTIC ANTITUMOR ACTIVITY OF THE BCMA 2 + 1 T CELL ENGAGER (TCE) ALNUCTAMAB (ALNUC; BMS-986349; CC-93269) AND CELMOD AGENTS IN MULTIPLE MYELOMA (MM) PRECLINICAL MODELS

HemaSphere2023-08-011 citations

P825: SOLUBLE FACTORS CORRELATED WITH CYTOKINE RELEASE SYNDROME (CRS) WITH IV VS SUBCUTANEOUS (SC) ALNUCTAMAB (ALNUC; BMS-986349; CC-93269) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

HemaSphere2023-08-01

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Blood2022-11-1567 citations

Soluble Factors Correlated with High-Grade Cytokine Release Syndrome (CRS): A Comparison of Subcutaneous (SC) Versus Intravenous (IV) Delivery of Alnuctamab (ALNUC; BMS-986349; CC-93269) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood2022-11-155 citations

First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial

Blood2019-11-13158 citations